Drug intelligence / Profile preview

amlodipine + losartan potassium + hydrochlorothiazide

Development stage
Phase 3
Lead developer
Merck
Modality
Small Molecules
Administration
Oral
01

Overview

Amlodipine + losartan potassium + hydrochlorothiazide is a fixed-dose combination medication used primarily for the treatment of hypertension (high blood pressure). It combines three antihypertensive agents with complementary mechanisms: - **Amlodipine** is a calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle. This action relaxes blood vessels and lowers blood pressure. - **Losartan potassium** is an angiotensin II receptor blocker (ARB) that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking its binding to the AT1 receptor in many tissues. This leads to vasodilation and reduced blood pressure. - **Hydrochlorothiazide** is a thiazide diuretic that increases excretion of sodium and water by inhibiting sodium reabsorption in the distal tubules. This reduces plasma volume and decreases blood pressure. The combination provides additive antihypertensive effects through these distinct pathways. Lowering high blood pressure helps prevent strokes, heart attacks, heart failure, kidney failure, and other complications associated with chronic hypertension[1][2][5].

Brand names
Amlozaar-HTrilopaceAmlonis HNusar AmhResitan AmhAsomex LthAmlosar HCamlosar HDipress HLAdblock LH
Other names
amlodipine + losartan potassium + hydrochlorothiazide
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on amlodipine + losartan potassium + hydrochlorothiazide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amlodipine + losartan potassium + hydrochlorothiazide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call